Apogee CMO swaps 167K shares at $135.11
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. (APGE) reports that Chief Medical Officer Carl Dambkowski disposed of common stock and stock options in early September 2026, primarily in connection with the cash merger of Apogee with an AbbVie Inc.–affiliated entity under an Agreement and Plan of Merger.
Insider Trade Summary
Disposition: 487,815 shares
Disposition
5 txns
Insider
Dambkowski Carl
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F3, F2 | 110,665 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3, F2 | 124,962 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3, F2 | 83,690 | -- | -- |
| Disposition | Common Stock F1 | 167,123 | -- | -- |
| Disposition | Common Stock | 1,375 | $135.06 | $186K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
- F2. The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
- F3. Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Key Figures
Common stock disposed in merger: 167,123 shares
Separate common stock sale: 1,375 shares
Stock options disposed (22.86 strike): 110,665 shares underlying
+4 more
7 metrics
Common stock disposed in merger
167,123 shares
Common shares exchanged for cash under the Agreement and Plan of Merger
Separate common stock sale
1,375 shares
Disposed on September 2, 2026 at $135.06 per share
Stock options disposed (22.86 strike)
110,665 shares underlying
Options with $22.86 exercise price cashed out in merger
Stock options disposed (49.07 strike)
124,962 shares underlying
Options with $49.07 exercise price cashed out in merger
Stock options disposed (75.78 strike)
83,690 shares underlying
Options with $75.78 exercise price cashed out in merger
Per share merger consideration
$135.11
Cash consideration per Apogee share used to value option cash-outs
Option expiration dates
December 18, 2033; December 9, 2034; January 2, 2036
Original expiration dates of option grants that were cashed out
Key Terms
Agreement and Plan of Merger, per share merger consideration, vested
3 terms
Agreement and Plan of Merger regulatory
"disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
vested financial
"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did APGE’s Chief Medical Officer report in this Form 4?
Chief Medical Officer Carl Dambkowski reported disposing of Apogee Therapeutics common stock and stock options in early September 2026, largely in exchange for cash pursuant to an Agreement and Plan of Merger with AbbVie Inc.–related entities, plus a separate sale of 1,375 shares.
What stock option awards of APGE were cashed out in the AbbVie merger?
Three vested option awards covering 110,665 shares at $22.86, 124,962 shares at $49.07, and 83,690 shares at $75.78 were disposed of in the merger in exchange for cash equal to the excess of the $135.11 per share merger consideration over each option’s exercise price.
Were the APGE insider transactions made under a Rule 10b5-1 trading plan?
No. The filing indicates that the transactions were not made pursuant to a Rule 10b5-1 trading plan, so there is no representation that these dispositions followed a pre-arranged trading schedule under that rule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
